This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G23.1 | Special Copayment Reduction: V190 | Coverage period: 5 years |
| B. Synonyms | Steele-Richardson-Olszewski syndrome, PSP, progressive supranuclear palsy, Parkinson-plus syndrome |
| C. Adult onset | Likelihood of first onset in adulthood: very high — onset mostly in the 60s–70s; onset before the 40s is rare |
| 1. History | 1964 first described by Steele-Richardson-Olszewski; 4R tau accumulation established as the pathological mechanism |
| 2. Causes | MAPT gene H1 haplotype as a risk factor; abnormal accumulation of 4-repeat tau (4R-tau) protein is the core pathology |
| 3. Genetics | Mostly sporadic; MAPT H1/H1 homozygosity is a strong risk factor; familial cases rarely reported |
| 4. General epidemiology | Prevalence 5–6 per 100,000; annual incidence 5–6/100,000; peak in the 60s–70s |
| 5. Pathophysiology | MAPT H1 haplotype → 4R tau overexpression → neurofibrillary tangle formation → neuronal death in the midbrain·basal ganglia·frontal lobe |
| 6. Symptoms | Early frequent falls (backward), supranuclear vertical gaze palsy, axial rigidity, cognitive-behavioral abnormalities |
| 7. Signs | Impaired vertical downgaze, axial dystonia (neck extension posture), frontal lobe symptoms, upper motor neuron signs |
| 8. Screening | Early diagnostic pathway based on clinical suspicion; brain MRI (midbrain atrophy), plasma p-tau217 biomarker under study |
| 9. Diagnosis | MDS-PSP diagnostic criteria (2017), brain MRI (hummingbird·Mickey Mouse signs), tau PET, CSF biomarkers |
| 10. Treatment | No established disease-modifying treatment; limited levodopa response; centered on fall prevention·rehabilitation·management of dysarthria |
| 11. Prognosis | Mean survival after diagnosis 6–10 years; causes of death mainly aspiration pneumonia and respiratory failure |
| 12. Prevention | No established prevention; fall prevention, early rehabilitation intervention, and prevention of aspiration pneumonia are the core of secondary prevention |
| 13. References | Steele JC et al. Medicine 1964 and 9 other papers |
Progressive supranuclear palsy (PSP) was first defined clinically and pathologically as an independent disease in 1964 in a landmark paper published in Archives of Neurology by John C. Steele, J. Clifford Richardson, and Jerzy Olszewski. They described 9 patients who showed supranuclear eye movement disorder, pseudobulbar palsy, cervical dystonia, mild dementia, and parkinsonism-like symptoms but did not respond to levodopa. Pathoanatomically, accumulation of neurofibrillary tangles (NFT) was found in the tectal plate of the midbrain, globus pallidus, subthalamic nucleus, and substantia nigra. The disease subsequently also came to be called Steele-Richardson-Olszewski (SRO) syndrome. In 1994, NACP (National Institute of Neurological Disorders and Stroke) and SPSP (Society for Progressive Supranuclear Palsy) jointly presented diagnostic criteria for PSP. With advances in molecular biology, in the late 1990s the main pathological protein of PSP was found to be 4-repeat tau (4R-tau), and the H1 haplotype of the MAPT (microtubule-associated protein tau) gene was identified as a major risk factor. In 2017, the International Parkinson and Movement Disorder Society (MDS) published new PSP diagnostic criteria, expanding the clinical spectrum of PSP and emphasizing early diagnosis.
The direct cause of PSP has not yet been fully elucidated, but abnormal hyperphosphorylation and misfolding of 4-repeat tau (4R-tau) protein and the formation of insoluble aggregates within neurons·astrocytes·oligodendrocytes are the core pathological mechanisms. Normally, tau protein is a cytoskeletal protein needed for microtubule stabilization, but in PSP its binding to microtubules is weakened and intracellular phosphorylated tau filaments accumulate as neurofibrillary tangles (NFT). PSP is classified as a 4R tauopathy in which the 4-repeat tau isoform (4R tau including exon 10) is overproduced. The H1 haplotype of the MAPT (microtubule-associated protein tau) gene is the strongest known genetic risk factor for PSP, and about 95% of PSP patients are H1/H1 homozygotes. The H1 haplotype increases the proportion of the 4-repeat tau isoform in tau mRNA, which predisposes to the formation of 4R tau pathology. Heavy metal exposure, head trauma, oxidative stress, and others have been proposed as environmental factors, but no clear causal relationship has been established. A cluster of an atypical parkinsonism-PSP-like syndrome has been observed on the island of Guadeloupe, and a neurotoxin (annonacin) contained in plants native to this region (genus Annona) has been proposed to induce tau pathology.
PSP is mostly a sporadic disease, and familial PSP caused by a clear single-gene mutation is very rare. The most important genetic risk factor is the H1 haplotype of the MAPT gene. In the chromosome 17q21.31 region where the MAPT gene is located, there are two dominant haplotypes, H1 and H2, formed by a large genomic inversion. The H1 haplotype increases expression of 4-repeat tau mRNA, while the H2 haplotype lowers overall MAPT expression and the 4R/3R tau ratio. Homozygosity for the H1 haplotype (H1/H1) raises the risk of PSP about 3–6-fold compared with H2 carriers. A study published in 2024 explored correlations between detailed sub-haplotypes within the H1 haplotype (H1c, H1g, etc.) and PSP phenotypic subtypes. In GWAS (genome-wide association study) research, risk loci other than MAPT, such as STX6, EIF2AK3, MOBP, DUSP10, and RUNX2, have been identified, but the effect size of each is small. In familial PSP cases, rare high-penetrance mutations of the MAPT gene itself (e.g., N279K, P301L) have been found in some cases, but these often overlap clinically with frontotemporal dementia (FTD). Besides genetic risk, there are epidemiological studies suggesting that age of onset, a history of head trauma, educational level, and other factors may influence the development of PSP.
PSP is the most common of the Parkinson-plus syndromes after multiple system atrophy (MSA) and accounts for a considerable proportion of neurodegenerative movement disorders. Prevalence is reported at about 5–6 per 100,000 population, and studies associated with the Queen Square Brain Bank in the UK have estimated up to 6.5 per 100,000. The annual incidence is about 5–6 per 100,000. Onset is mostly in the 60s–70s (mean about 63–68 years), and onset before age 40 is very rare. Men tend to be affected about 1.5–2 times more often than women, but recent studies have also reported a narrowing sex difference. Epidemiological data on PSP in Korea are limited, but studies based on health insurance data estimate prevalence to be somewhat lower than in the West. There is generally no regional clustering, but the atypical parkinsonism-PSP-like syndrome on Guadeloupe is an exceptional cluster. PSP is often misdiagnosed as Parkinson disease early on, and the mean diagnostic delay is known to be about 3–4 years. The number of PSP patients is expected to increase with population aging.
The core pathophysiology of PSP is selective neuronal death due to abnormal accumulation of 4-repeat tau (4R-tau) protein. Normally, tau stabilizes microtubules in neuronal axons, and in the brain two forms, 3-repeat tau (3R) and 4-repeat tau (4R), exist in nearly equal proportions through alternative splicing of exon 10. In PSP, under the influence of the MAPT H1 haplotype, the 4R tau isoform is overexpressed, and when this 4R tau is hyperphosphorylated, its affinity for microtubules decreases and it aggregates in the cytoplasm as oligomers and insoluble filaments. These pathological tau aggregates appear in various forms, such as neurofibrillary tangles (NFT), coiled bodies in oligodendrocytes, and tufted astrocytes. This pathology is selectively severe in the midbrain tectum (superior colliculus, controlling eye movement), pontine nuclei, basal ganglia (globus pallidus, subthalamic nucleus, striatum), substantia nigra, and frontal cortex. Cell-to-cell spread of tau pathology (prion-like spreading) has been proposed as a model explaining lesion spread. Neuroinflammation (activation of microglia and reactive astrocytes) is also being studied as a contributor to the progression of tau pathology. Mitochondrial complex I dysfunction has also been reported as an element of PSP pathogenesis.
The clinical symptoms of PSP appear as a multidomain combined disorder of motor, eye movement, cognitive, behavioral, and bulbar functions. The core clinical triad (cardinal triad) is (1) supranuclear vertical gaze palsy (especially impaired downgaze), (2) frequent falls (especially falling backward), and (3) axial dystonia (rigidity of the neck and trunk, mainly in an extended posture). Falls are a very early symptom of PSP, and repeated unexplained falls within 1 year of onset are an important clue to suspect PSP. Early on, it presents with Parkinson disease-like bradykinesia and gait disturbance and is often misdiagnosed as Parkinson disease. However, unlike the stooped posture of Parkinson disease, the gait disturbance of PSP is characterized by an extended neck and trunk (posture tilted backward). As cognitive abnormalities, frontal lobe dysfunction (executive dysfunction, slowed cognitive speed) and apathy are prominent, while memory is relatively preserved. Dysarthria (low voice, slurred speech, palilalia) and dysphagia may appear from the early stage. Sleep disorders (REM sleep behavior disorder is rare), blepharospasm, and apraxia of eyelid opening are also observed. Various clinical phenotypic subtypes have been described, such as PSP-parkinsonism (PSP-P) and PSP-pure akinesia with gait freezing (PSP-PAGF).
On physical examination, the most characteristic sign of PSP with high diagnostic value is supranuclear vertical gaze palsy. In particular, impairment of downward vertical gaze appears earlier and more severely, and this is more specific for PSP than impaired upgaze. A positive doll's eye phenomenon (eye movements are preserved when the head is moved passively) confirms a supranuclear lesion. Axial rigidity is prominent in the neck, and marked resistance is felt when trying to flex or rotate the neck passively. The trunk is also rigid in an extended posture. Backward falls due to postural instability are characteristic, and the backward-falling response on the pull test is marked. Frontal lobe signs may include the grasp reflex, palmomental reflex, and apraxia. Upper motor neuron signs may include hyperreflexia and a positive Babinski sign. The rigidity is closer to lead-pipe rigidity than to the cogwheel rigidity of Parkinson disease and predominates in the trunk and neck rather than the limbs. Levodopa response, if present, is limited (loss of effect after an early transient response), and this is an important clinical point distinguishing it from Parkinson disease.
There is currently no population screening for PSP. The clinically important early diagnosis strategy is to suspect PSP early in patients presenting with parkinsonism-like symptoms. Clues for early suspicion are: (1) unexplained backward falls within 1 year of onset, (2) parkinsonism unresponsive to levodopa from the start, (3) dysarthria prominent from early on, (4) early cognitive decline or apathy, and (5) impaired vertical gaze (especially downward). When these signs are identified, systematic clinical evaluation according to the MDS-PSP criteria and brain MRI are carried out immediately. Confirmation of midbrain atrophy (hummingbird sign or Mickey Mouse sign) on brain MRI supports early diagnosis. In terms of plasma and CSF biomarkers, elevation of tau protein (especially p-tau231, p-tau217) and neurofilament light chain (NfL) is being studied for use in monitoring neurodegeneration and the course of PSP. Tau PET (positron emission tomography) imaging shows increased 4R tau signal in the midbrain, basal ganglia, and frontal lobe of PSP patients and is a promising tool for early diagnosis and classification. Once clinical validation of blood tau biomarkers is complete, they may be used as screening tools in high-risk elderly populations.
For PSP diagnosis, the MDS-PSP criteria published in 2017 by the International Parkinson and Movement Disorder Society (MDS) are currently used as the standard. These criteria classify the core clinical features in four functional domains (ocular motor, postural stability, motor function, cognitive function) into mandatory (O), exclusionary (X), supportive (S), and excluded (E) items to distinguish the various clinical phenotypic subtypes of PSP (PSP-RS, PSP-P, PSP-F, PSP-SL, PSP-OM, PSP-CBS, PSP-PAGF). Brain MRI is the key imaging diagnostic tool; the "hummingbird sign", showing reduced midbrain area and a reduced midbrain/pons ratio on sagittal T1 images, or the "Mickey Mouse sign" on axial images strongly suggests PSP. Reduction in midbrain area on MRI (normal ~110mm2 vs. PSP ~55mm2) can be quantified. On FDG-PET, reduced glucose metabolism in the midbrain and frontal lobe is characteristic. Tau PET ([18F]-flortaucipir, [18F]-PI-2620, etc.) visualizes 4R tau accumulation in the basal ganglia, midbrain, and frontal lobe, increasing the diagnostic accuracy for PSP, and is useful for early diagnosis and monitoring of treatment response. On CSF testing, total tau and phosphorylated tau are lower than in Alzheimer disease and may be close to normal, while NfL is significantly elevated. Serum NfL is also being studied as a biomarker for diagnosis and follow-up of the course.
There is currently no approved disease-modifying treatment for PSP. Levodopa shows a transient early effect in relieving parkinsonian symptoms in some PSP patients (30–40%), but over the long term the response is often lost or absent from the start. Nevertheless, a levodopa trial (up to 1,200mg/day) early in diagnosis to assess response is recommended. Botulinum toxin injection is effective for dystonia (blepharospasm). Numerous clinical trials targeting tau have been conducted in the past (tau aggregation inhibitors, tau immunotherapy, ASOs, etc.), but to date no clinical trial has shown a significant effect in PSP. Fall prevention is the most important practical task in PSP treatment, and mobility aids (rolling walker, quad cane), fall-protection vests, and home environment modification are recommended. Rehabilitation (physical therapy: gait training, balance training; occupational therapy: adaptation for daily living; speech therapy: articulation, swallowing, AAC) is important for maintaining function. When dysphagia worsens, a nasogastric tube or gastrostomy is considered. Drug treatment of nonmotor symptoms such as apathy, depression, and sleep disorders also contributes to maintaining quality of life. Linkage with palliative care and hospice is essential for end-of-life management.
PSP is a progressive, fatal neurodegenerative disease, with a mean survival after diagnosis of about 6–10 years. However, counted from symptom onset it is about 5–8 years, and it differs by phenotype. The PSP-RS (Richardson syndrome) variant is the most common (about 54%) and has the worst prognosis, while PSP-P (parkinsonian type) has an early levodopa response and slower progression, giving a relatively better prognosis. The main causes of death are aspiration pneumonia (aspiration due to dysphagia), urinary tract infection (a complication of immobility), and respiratory failure. In terms of functional prognosis, PSP patients tend to need a walking aid within a mean of 3–4 years after onset and become wheelchair-dependent within 5–6 years. Cognitive decline also worsens in the later stages of the disease. Because head trauma and fractures from falls are major causes of morbidity, fall prevention contributes greatly to improving prognosis. There are study results showing that care at a multidisciplinary specialized PSP clinic is beneficial for maintaining quality of life and survival. Numerous clinical trials are currently under way, and there is hope that prognosis may improve with the future development of disease-modifying treatments.
There is currently no established method for primary prevention of PSP. Because, as a sporadic disease, it is not caused by a specific gene variant, the role of genetic counseling or prenatal diagnosis is extremely limited. In the rarely found familial PSP with MAPT mutations, genetic counseling and predictive genetic testing are possible. Secondary prevention (prevention of complications) is currently the core of PSP management. Prevention of falls and head trauma is the most important secondary prevention activity in PSP patients, and appropriate use of mobility aids, removal of hazards in the home (carpets, door thresholds, slippery floors), bathroom safety equipment (grab bars, nonslip mats), and use of fall alarm devices are recommended. To prevent aspiration pneumonia, swallowing is assessed regularly, food texture is adjusted to the progression of dysphagia, and oral hygiene is managed thoroughly. Nutrition via gastrostomy (PEG) reduces aspiration risk and helps maintain weight. Influenza and pneumococcal vaccinations contribute to pneumonia prevention. To prevent urinary tract infections, maintaining fluid intake and appropriate bowel management are important. Mental activities to maintain cognitive function (reading, conversation, cognitive training) are also recommended.